In the sixth in a series of debates about the world’s HIV response hosted by the World Bank and USAID, physician-scientists debated how best to transform the exciting results from the HPTN) 052 study, which demonstrated that those with HIV infection who received immediate treatment with antiretroviral therapy (ART) were 96 percent less likely to transmit HIV to their uninfected sexual partners than those whose treatment was delayed. The panelists were tasked with debating not only how to apply treatment as prevention (TasP) quickly, and how to add it to the combination prevention tool kit effectively, but more so whether or not it makes sense to have countries spend a majority of what is likely to be a flat or declining HIV prevention budget on TasP.
The goals of controlling HIV sound like a straight forward series of three consecutive steps, one following another, when discussed in global and domestic epidemic-ending plans. […]
The announcement Wednesday of U.S. Food and Drug Administration approval of pretomanid, a new tuberculosis drug that has been part of a ground-breaking treatment regimen against […]
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
The following is a guest post by Jacqueline Hellen and Lisa Parker of MEASURE Evaluation While programs in low- and middle-income countries seek to support children […]